| Literature DB >> 24056489 |
Olivier Vandenplas1, Vinciane D'Alpaos, Geneviève Evrard, Jacques Jamart, Joel Thimpont, François Huaux, Jean-Christophe Renauld.
Abstract
OBJECTIVE: To determine the agents causing asthmatic reactions during specific inhalation challenges (SICs) in workers with cleaning-related asthma symptoms and to assess the pattern of bronchial responses in order to identify the mechanisms involved in cleaning-related asthma.Entities:
Keywords: Bronchoprovocation tests; Cleaning; Occupational disease
Year: 2013 PMID: 24056489 PMCID: PMC3780339 DOI: 10.1136/bmjopen-2013-003568
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Demographic, occupational and clinical characteristics of the participants
| Positive SIC (n=17) | Negative SIC (n=27) | p Value | |
|---|---|---|---|
| Gender (female) | 13 (76) | 23 (85) | 0.466 |
| Age, years* | 47 (39–49) | 47 (35–53) | 0.942 |
| Referral by WCB | 13 (76) | 20 (74) | 0.858 |
| Job/industry | |||
| Professional cleaners | 9 | 15 | |
| Healthcare facilities | 2 | 5 | |
| Various industries | 3 | 4 | |
| Private houses | 1 | 3 | |
| Public buildings | 2 | 2 | |
| Kitchens | 1 | 1 | |
| Healthcare workers | 7 | 9 | |
| Food workers | 1 | 2 | |
| Pharmaceutical workers | 0 | 1 | |
| Exposure to respiratory sensitisers | 16 (94) | 16 (59) | 0.033 |
| QAC | 10 | 6 | |
| QAC and glutaraldehyde | 1 | 3 | |
| Glutaraldehyde | 3 | 7 | |
| Ethanolamines | 2 | 0 | |
| No identified sensitiser | 1 | 11 | |
| Current and ex-smokers | 6 (35) | 8 (30) | 0.694 |
| Atopy† | 7 (41) | 13 (48) | 0.651 |
| Asthma pre-existing to exposure | 2 (12) | 2 (7) | 0.624 |
| Duration of exposure before the onset of asthma, months* | 12 (5–153) | 53 (31–165) | 0.114 |
| Duration of asthma before SIC, months* | 25 (7–59) | 25 (10–55) | 0.980 |
| Delay since last work exposure, months* | 10 (0.3–16) | 8 (0.1–24) | 0.808 |
| Work-related respiratory symptoms | |||
| Wheezing | 14 (82) | 14 (52) | 0.056 |
| Breathlessness | 14 (82) | 20 (74) | 0.716 |
| Cough | 11 (65) | 21 (78) | 0.343 |
| Chest tightness | 11 (65) | 18 (67) | 0.893 |
| Sputum | 4 (24) | 8 (30) | 0.740 |
| Work-related rhinitis | 8 (47) | 16 (59) | 0.429 |
| Work-related dermatitis | 5 (29) | 5 (19) | 0.401 |
| Inhaled corticosteroid | |||
| Number with inhaled corticosteroid | 13 (76) | 15 (56) | 0.160 |
| Low dose‡ | 3 (18) | 5 (19) | |
| Medium dose‡ | 5 (29) | 5 (19) | 0.494 |
| High dose‡ | 5 (29) | 5 (19) | |
| Short-acting β2-agonist≥once a day | 7 (41) | 1 (4) | 0.002 |
| Baseline FEV1,% predicted* | 92 (73–101) | 100 (88–109) | 0.049 |
| Baseline FEV1/FVC, %* | 71 (63–77) | 80 (73–83) | 0.002 |
| Baseline airway obstruction§ | 5 (29) | 1 (4) | 0.016 |
Data are presented as n (% of available data) unless otherwise specified.
*Median value with 25th–75th IQR in parentheses.
†Atopy defined by a positive skin-prick test to at least one common inhalant allergen.
‡Low dose: equal or less than 500 µg beclomethasone dipropionate equivalent/day; medium dose: more than 500 µg but equal or less than 1000 µg/day; and high dose: more than 1000 µg/day.
§Airway obstruction defined by an FEV1 <80% predicted value and an FEV1/FVC ratio <70%.
FEV1, forced expiratory volume in one-second; FVC, forced vital capacity; PC20, provocative concentration of histamine causing a 20% fall in FEV1; QAC, quaternary ammonium compound; SIC, specific inhalation challenge; WCB, workers' compensation board.
Changes in non-specific airway responsiveness and sputum cells during inhalation challenges with cleaning agents
| Positive SIC | Negative SIC | |||||
|---|---|---|---|---|---|---|
| Baseline | Postchallenge | p Value | Baseline | Postchallenge | p Value | |
| AHR to histamine | (n=17) | (n=12) | (n=27) | (n=25) | ||
| PC20, mg/mL | 1.4 (0.2–4.22) | 0.5 (0.4–3.0)* | 0.019 | 13.0 (1.4–32.0) | 16.9 (2.6–32.0) | 0.267 |
| PC20 >16 mg/mL† | 2 (12) | 0 | 13 (48) | 13 (52) | ||
| >Threefold decrease in PC20† | 5 (42) | 0 | ||||
| Sputum cell counts‡ | (n=13) | (n=13) | (n=7) | (n=7) | ||
| Total cell count, 106/mL | 0.54 (0.34–0.97) | 1.15 (0.53–2.17) | 0.041 | 0.34 (0.26–1.89) | 0.65 (0.38–1.81) | 0.735 |
| Eosinophils, 106 cells/mL | 0.02 (0.01–0.04) | 0.12 (0.02–0.39) | 0.006 | 0 (0–0.01) | 0 (0–0.01) | 0.345 |
| Eosinophils, % | 1.8 (0.8–7.2) | 10.0 (4.1–15.9) | 0.009 | 0.2 (0–2.5) | 0.8 (0.2–1.5) | 0.786 |
| Increase in eosinophils >2%† | 8 (62) | 0 | ||||
| Neutrophils, 106 cells/mL | 0.40 (0.17–0.70) | 0.71 (0.38–1.62) | 0.009 | 0.19 (0.16–1.70) | 0.34 (0.25–1.52) | 0.866 |
| Neutrophils,% | 57.3 (42.4–72.5) | 69.5 (56.9–83.0) | 0.152 | 60.3 (55.7–83.0) | 70.3 (52.5–84.0) | 0.866 |
Data are presented as median value with 25–75th IQR in parentheses unless otherwise specified.
*Histamine PC20 was measured at 7 h after the end of exposure in six participants and 24 h postexposure in six participants with positive SIC.
†Data expressed as n (% of available data).
‡Data available on participants who performed an SIC from 2006 onwards.
AHR, airway hyper-responsiveness; PC20, provocative concentration of histamine causing a 20% fall in FEV1; SIC, specific inhalation challenge.